Parkinson’s disease and Huntington’s disease are caused by the death of nerve cells in the part of the brain called basal ganglia.
Our goal is to develop and improve treatments for the diseases and to improve quality of life for patients and their families.
The Swedish Research Council and Formas have now completed an interim evaluation of the 20 Linneaus Environments that were awarded grants in 2008, including Bagadilico. The overall results show an impressively high quality. Bagadilico is praised particularly for its ability to boost the careers of promising young researchers, and the ability take basic research discoveries all the way towards clinical application.
Two years ago, a new type of stem cell was discovered in the brain that has the capacity to form new cells. The same research group at Lund University in Sweden has now revealed that these stem cells, which are located in the outer blood vessel wall, appear to be involved in the brain reaction following a stroke.
In Parkinson’s disease, the dopamine-producing nerve cells that control our motor function waste away. The research to develop new treatments therefore often aims to save or restore these cells. In a new study from BAGADILICO affiliates, researchers are attacking the disease from a different angle through early activation of the brain’s defence mechanisms. Stimulating a specific protein, the Sigma-1 receptor, sets off a battery of self-healing effects that slow the progression of the disease and restore the lost motor function. The results have been produced in studies on mice, but clinical trials with patients are not far off.